IL270840A - Nk-92 cells and il-15 agonist combination therapy - Google Patents

Nk-92 cells and il-15 agonist combination therapy

Info

Publication number
IL270840A
IL270840A IL270840A IL27084019A IL270840A IL 270840 A IL270840 A IL 270840A IL 270840 A IL270840 A IL 270840A IL 27084019 A IL27084019 A IL 27084019A IL 270840 A IL270840 A IL 270840A
Authority
IL
Israel
Prior art keywords
agonist
cells
combined therapy
therapy
combined
Prior art date
Application number
IL270840A
Other languages
English (en)
Hebrew (he)
Inventor
Laurent Boissel
Tien Lee
Hans Klingemann
Original Assignee
Nantkwest Inc
Laurent Boissel
Tien Lee
Hans Klingemann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nantkwest Inc, Laurent Boissel, Tien Lee, Hans Klingemann filed Critical Nantkwest Inc
Publication of IL270840A publication Critical patent/IL270840A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL270840A 2017-06-20 2019-11-21 Nk-92 cells and il-15 agonist combination therapy IL270840A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762522319P 2017-06-20 2017-06-20
PCT/US2018/038312 WO2018236890A1 (en) 2017-06-20 2018-06-19 Nk-92 cells and il-15 agonist combination therapy

Publications (1)

Publication Number Publication Date
IL270840A true IL270840A (en) 2020-01-30

Family

ID=62875319

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270840A IL270840A (en) 2017-06-20 2019-11-21 Nk-92 cells and il-15 agonist combination therapy

Country Status (9)

Country Link
US (1) US20200121720A1 (enExample)
EP (1) EP3641799A1 (enExample)
JP (1) JP2020524167A (enExample)
KR (1) KR20200017495A (enExample)
CN (1) CN110740747A (enExample)
AU (1) AU2018288715A1 (enExample)
CA (1) CA3066465A1 (enExample)
IL (1) IL270840A (enExample)
WO (1) WO2018236890A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022250312A1 (ko) * 2021-05-27 2022-12-01 (주)에스엠티바이오 신경내분비종양의 치료용 자연살해세포

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1690927A1 (en) 1997-04-30 2006-08-16 Hans Klingemann Natural killer cell lines and methods of use
WO2005085282A1 (en) 2004-02-27 2005-09-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Il-15 binding site for il15-ralpha and specific il-15 mutants having agonists/antagonists activity
AU2008253720B2 (en) 2007-05-11 2014-01-16 Altor Bioscience Corporation Fusion molecules and IL-15 variants
WO2012040323A2 (en) 2010-09-21 2012-03-29 Altor Bioscien Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same

Also Published As

Publication number Publication date
CN110740747A (zh) 2020-01-31
JP2020524167A (ja) 2020-08-13
EP3641799A1 (en) 2020-04-29
KR20200017495A (ko) 2020-02-18
US20200121720A1 (en) 2020-04-23
CA3066465A1 (en) 2018-12-27
AU2018288715A1 (en) 2019-12-12
WO2018236890A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
IL323656A (en) Neoantigens and methods for using them
PL3618842T3 (pl) Kombinacja terapii komórkowej i związku immunomodulującego
IL270990A (en) Expression of novel cell tags
IL271025A (en) Multibiotic agents and methods of using the same
PL3601358T3 (pl) Przeciwciała anty-trem2 i sposoby ich wykorzystania
EP3678681A4 (en) INTERLEUKIN-18 VARIANTS AND THEIR PROCEDURES FOR USE
HUE065695T2 (hu) Szövet életképesség mérése
PL3694529T3 (pl) Trójswoiste białka i sposoby zastosowania
DK3449945T3 (da) Stof indeholdende guldklynge og fremstillingsfremgangsmåde og anvendelse deraf
IL259441A (en) Materials and methods for treatment of titin-based myopathies and other titinopaties
PL3598537T3 (pl) Sposób wytwarzania mieszaniny elektrodowej oraz mieszanina elektrodowa
IL269334A (en) Improved t cell compositions and methods
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
PL3250610T3 (pl) Przeciwciała anty-FcRn i sposoby ich stosowania
EP3686275A4 (en) GENE EDITING LYMPHOCYTE T AND RELATED USE
PL3160498T3 (pl) Cząsteczki na bazie IL-15 i sposoby ich zastosowania
CL2016001432A1 (es) Nuevos anticuerpos anti-dpep3 y métodos de uso
MX2016005631A (es) Anticuerpos anti-alfa-sinucleina y metodos de uso.
PL3583644T3 (pl) Materiały elektrodowe i sposoby ich wytwarzania
PL3411021T3 (pl) Nowe zastosowanie kombinacji sakubitrylu i walsartanu
EP3683275A4 (en) CONDUCTIVE COMPOSITION AND BIOSENSOR
EP3590929A4 (en) SPIRO COMPOUND AND ITS USE
PL3720875T3 (pl) Peptydy przeciwdrobnoustrojowe i sposoby ich stosowania
MA49905A (fr) Polyesteramines et polyesterquats
EP3671088C0 (en) PORTABLE CLOTHES DRYING APPARATUS AND METHOD OF USE